Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD
Status:
Completed
Trial end date:
2020-04-03
Target enrollment:
Participant gender:
Summary
The objective of this Phase IIa study is to assess the safety, tolerability, and efficacy of
incremental doses of MGB-BP-3 in patients with Clostridium difficile-associated diarrhea
(CDAD).